Last updated on June 2019

INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)


Brief description of study

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period.  In the LTS period,  participants initially randomized to vehicle will receive either ruxolitinib 0.75% or 1.5% cream.  All participants will have follow-up assessments 30 (+7) days after the last application of study drug

 

Detailed Study Description

NCT03745638

Clinical Study Identifier: TX221555

Find a site near you

Start Over

WEST END DERMATOLOGY

Located in: HENRICO, VA United States
3.88miles
  Connect »